| Name | Title | Contact Details |
|---|
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient`s immune system to treat cancer. INKmune, the company`s lead product, primes patient`s NK cells (natural killer cells) to kill cancer.
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.